Skip to main content
PDS Biotechnology Corp logo

PDS Biotechnology Corp — Investor Relations & Filings

Ticker · PDSB ISIN · US2798701098 LEI · 5493002KU8ACFTSMC935 US Mining and quarrying
Filings indexed 747 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country US United States of America
Listing US PDSB

About PDS Biotechnology Corp

https://www.pdsbiotech.com

PDS Biotechnology Corp. is a clinical-stage immunotherapy company developing treatments designed to harness the body's T cells to combat disease. The company's proprietary Versamune® platform is a T-cell activating technology engineered to generate a potent and targeted immune response. The platform's mechanism involves delivering immune-activating agents, such as IL-12, into the tumor microenvironment to overcome cancer's defense mechanisms while stimulating a powerful T-cell attack. PDS Biotechnology's pipeline includes investigational immunotherapies for various cancers, including head and neck, prostate, and breast cancer, as well as potential vaccines for infectious diseases.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report
2026-05-14 English
8-K - PDS Biotechnology Corp (0001472091) (Filer)
Regulatory Filings
2026-05-13 English
8-K - PDS Biotechnology Corp (0001472091) (Filer)
Regulatory Filings
2026-05-01 English
S-3/A - PDS Biotechnology Corp (0001472091) (Filer)
Registration Form
2026-04-27 English
8-K - PDS Biotechnology Corp (0001472091) (Filer)
Regulatory Filings
2026-04-15 English
8-K - PDS Biotechnology Corp (0001472091) (Filer)
Regulatory Filings
2026-03-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.